Presentatie - vzw farmaka asbl

Stents
30.Brophy. Evidence for use of coronary stents. A hierarchical Bayesian meta-analysis. Ann Intern Med 2003;138:777-86
Design N/n Population Sd Interventions Outcomes Results
MA N=29,
n=9918
-Stable or
unstable angina
-6 to 16
months
-PTCA with stent
-PTCA without stent
Mortality -1.2% (zonder stent) vs 0.8%
-OR= 0.69 (95%CI 0.43 to 1.05)
Mortality OR MI -ARD= - 0.50% in favour of stent
-OR= 0.90 (95%CI 0.72 to 1.11)
CABG OR= 1.01 (95%CI 0.79 to 1.31)
Angiographic
restenosis
-40% (zonder stent) vs 27%
(ongecorrigeerde cijfers)
-ARD= 14.5% in favour of stent
-OR= 0.52 (95%CI 0.37 to 0.69)
Recurrent PTCA -ARD= 6.8% in favour of stent
-OR= 0.59 (95%CI 0.50 to 0.68)
ARD= absolute risk difference
Hill. Drug-eluting stents: a systematic review and economic evaluation. HTA 2007
Design N/n Population Sd Interventions Outcomes Results
MA N=17, -Coronary -Up to 3 -Bare metal stent Mortality
No differences
n>7000 artery disease years -Drug-eluting stent MI
No differences
(in most studies
Revascularisation Typically 5% (DES) vs 10 to 25%
exclusion of
(BMS) at 1 year
recent MI)
SS difference in favour of DES
Restenosis (> 50% SS difference in favour of DES
narrowing of lumen
after stenting)
www.farmaka.be
Project
Farmaka